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A B S T R A C T
Aquaculture now produces nearly half of the seafood consumed globally. Atlantic salmon (Salmo salar) is one of
the top aquaculture products and the most valuable farmed marine finfish species in the United States (U.S.). The
aim of this study is to better understand veterinary drug use in U.S. net pen Atlantic salmon aquaculture and
compare these findings to other salmon producing countries and U.S. livestock. We collected and analyzed
records on Atlantic salmon production and veterinary drug use in Maine (2003 to 2017) and Washington (2012
to 2017). Antimicrobial medicated feeds were used in 8% and 93% of production cycles in Maine and
Washington, respectively. Oxytetratcycline was the primary drug used in both states. Maine used no anti-
microbials in eight of the past 15 yrs., including none in 2017. Emamectin benzoate, an antiparasitic medicated
feed, was used in 28% production cycles in Maine (2014 to 2017; avg. 1.1 kg/yr) and no emamectin benzoate
was administered in Washington over the time period studied. From 2014 to 2016, the U.S. farmed salmon
industry contributed 0.8% ± 0.1% to annual global farmed salmon production and administered 1.2% ± 0.6%
of antimicrobials used in global salmon farming. Over the same time period, Norway and Chile accounted for
53% ± 3% and 35% ± 3% of annual global production, and administered 0.06% ± 0.02% and
96% ± 0.09% of antimicrobials used in global salmon farming. Compared to U.S. terrestrial agriculture in
2016, the U.S. Atlantic salmon industry contributed 0.031% to U.S. food animal production and administered
0.057% of antimicrobials available to U.S. food animals. Based on the data we collected, the U.S. Atlantic salmon
aquaculture industry is a relatively small user of antimicrobials compared to U.S. beef, pigs, poultry, and Chilean
salmon industries. There are relatively few approved drugs in the U.S. to treat aquaculture diseases and more
options are needed as well as continued work on vaccines. Antimicrobial resistance is a worldwide public health
concern; the overuse or misuse of antimicrobials in any setting can compromise the treatment of bacterial
infections. The U.S. net pen Atlantic salmon aquaculture industry appears to be the first U.S. food animal in-
dustry to report monthly antimicrobial use at the farm-level to the government. These data are critical to assess
public health risks associated with antimicrobial use and resistance, and therefore, are needed from all U.S. food
animal industries.
1. Introduction
Atlantic salmon (Salmo salar) were first commercially farmed in the
1960s in Norway (Tilseth et al., 1991) and now salmon farming has
become one of the most successful forms of aquaculture (Asche et al.,
2013). Farmed Atlantic salmon are cultured first in freshwater hatch-
eries as fry and parr, and are then transferred to seawater as smolts or
post-smolts for a grow-out period typically lasting up to two years.
During the grow-out period, fish are reared in net pens, which are
netted enclosures that are open to the surrounding aquatic environment
that allow for water exchange and for uneaten feed and waste to leave
the system. Over the past few decades, small salmon farms have been
replaced by a handful of large, vertically integrated companies that use
intensive farming methods that are comparable to the poultry industry
(Asche et al., 2016; Torrissen et al., 2011). The global salmon industry
produces over 2 million metric tons of fish each year, feeding millions
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of consumers in Europe, the United States (U.S.), Japan, and increas-
ingly in East and South East Asia (FAO, 2018; FAO GLOBEFISH, 2018).
The leading farmed salmon producing countries are Norway and Chile,
and the U.S. ranks 7th (Undercurrents News, 2018).
The focus of this paper is U.S. production, where Atlantic salmon is
the most valuable farmed marine finfish species, valued at $88 million
in 2015 (NOAA, 2017). Maine and Washington are the only states in the
U.S. where Atlantic salmon are raised commercially in marine net pens.
There is growing interest among the U.S. government and the aqua-
culture industry to move finfish aquaculture onland or to waters further
offshore (i.e., federal waters), in part to reduce a $14 billion seafood
trade deficit (NOAA, 2017), spur economic activity, and potentially
minimize some of the environmental externalities associated with near-
shore salmon production (Rust et al., 2014). There are no Atlantic
salmon farms currently in U.S. federal waters.
Disease is a top concern for the salmon aquaculture industry and a
potential impediment to future growth (Lafferty et al., 2015; Stentiford
et al., 2017). The major diseases impacting salmon production tend to
vary by producing region, and within regions over time. In Washington,
farmed salmon diseases known to exist include furunculosis (Aeromonas
salmonicida), yellow mouth (Tenacibaculum maritimum), vibriosis (Vibrio
spp.), salmon rickettsial syndrome (SRS) (Piscirickettsia salmonis), and
infectious hematopoietic necrosis (infectious hematopoietic necrosis
virus, IHNV) (Personal communication, Washington Department of Fish
and Wildlife). Washington fish are vaccinated for IHNV, Vibrio spp., and
A. salmonicida; however, vaccinated fish populations can still be af-
fected by clinical disease. There are no vaccines for SRS and yellow
mouth, and the only treatment option is tetracycline (Personal com-
munication, Washington Department of Fish and Wildlife). In Maine,
reported farmed salmon diseases include bacterial kidney disease (Re-
nibacterium salmoninarum) and infestation by sea lice (Lepeophtheirus
salmonis) ectoparasites. Similar disease challenges exist in other salmon
producing regions. Infectious salmon anaemia (ISA) has been associated
with catastrophic losses in the Canadian Maritimes (1990s) and Chile
(2000s), and while improvements in industry management have largely
reduced the occurrence of this disease in both regions, its potential
recurrence to previous levels remains a concern among producers. In
Norway, reports of infectious pancreatic necrosis (IPN, associated with
infectious pancreatic necrosis virus) have declined significantly over
the past two decades, whereas pancreatic disease (PD, associated with
salmonid alphavirus) has shown the opposite trend, and is now the
most reported viral disease (Hjeltnes et al., 2018). Likewise, certain
bacterial diseases that have historically impacted the Norwegian
salmon industry (Lillehaug et al., 2003), such as furunculosis (Aero-
monas salmonicida), cold water vibriosis (Vibrio salmonicida), and vi-
briosis (Vibrio anguillarum), are currently considered controlled, while
other bacterial diseases, namely yersiniosis (Yersinia ruckeri) and winter
ulcer (Moritella viscosa), as well as sea lice continue to be significant
problems for the industry (Hjeltnes et al., 2018).
In intensive aquaculture operations, producers and veterinarians
have a range of disease control options, including medicated feeds
containing antimicrobials and antiparasitics, chemical baths, vaccines
(for certain diseases), application of Labrid cleanerfish (fish used to
remove sea lice from farmed salmon), mechanical methods (such as
temporary changes in water temperature or salinity to combat external
parasites), and efficacious biosecurity and husbandry practices (Noga,
2011). A relatively small number of antibacterial agents are registered
for use in aquaculture in the U.S., Canada, and Europe. These include
members of the following classes of drugs: macrolides (erythromycin),
β-lactams (amoxicillin), fenicols (florfenicol), tetracyclines (oxyte-
tracycline), quinolones (oxolinic acid), fluoroquinolones (flumequine)
and potentiated sulphonamides (sulfadimethoxine/ormetoprim, sulfa-
diazine/trimetoprim) (Lunestad and Samuelsen, 2008; Metcalfe et al.,
2008; Treves-Brown, 2013). The only drugs approved for use in the U.S.
are oxytetracycline, florfenicol, and sulfadimethoxine/ormetoprim,
which is a challenge for farmers because there are relatively few options
available to treat diseases. These drugs are also from families listed as
“critically important” or “highly important” for human medicine by the
World Health Organization (WHO) (WHO, 2017b) and the U.S. Food
and Drug Administration (FDA) (FDA, 2003).
A particular concern in connection with the use of antimicrobials is
the development of resistant bacteria, causing antimicrobial resistance
genes in the environment as well as the piscine and human microbiome.
The development of antimicrobial resistance is a predictable, natural
process and ancient among bacteria (Aminov and Mackie, 2007;
D'Costa et al., 2011); however, the current global use of antimicrobial
agents in human and veterinary medicine, including terrestrial animal
agriculture and aquaculture, is an important driving force for increased
antimicrobial resistance selection and evolution (Marshall and Levy,
2011). A reduction in the use of antimicrobials is possible through
vaccination and improvements in husbandry practices, as shown in
Norway (Grave et al., 1999; Simonsen et al., 2013). Managing fish
health is crucial because of the linkages and interrelationship between
human health, animal health, and ecosystems. This concept is known as
One Health (Zinsstag et al., 2015) and is highly relevant when applied
to food animal production and antimicrobial resistance (Cabello et al.,
2016; Robinson et al., 2016).
Emamectin benzoate (EB) is an antiparasitic used to treat a fish
parasite called sea lice that affects farmed Atlantic salmon in some
regions. EB, known by the trade name SLICE ®, is the only che-
motherapeutic of its kind approved for use in the U.S.; the other sea lice
treatment used in the U.S. is a hydrogen peroxide bath. EB can have
toxic effects on aquatic animals biologically similar to the target spe-
cies, sea lice, such as crabs and lobsters (Tucca et al., 2014). The risk of
impacts to nontarget species is increased due to slow degradation and
potential build up of EB in the environment surrounding farmed salmon
operations (Benskin et al., 2016). Sustained use of EB and similar
compounds in countries with significant farmed salmon production
have led to development of sea lice populations with reduced sensitivity
to antiparasitics (Aaen et al., 2015; Lees et al., 2008). Sea lice infesta-
tions and reduced effectiveness of antiparasitics, including EB, has been
identified as one of the most significant challenges facing farmed
salmon companies around the world; sea lice may also facilitate bac-
terial infections and stimulate increased use of antimicrobials (Cabello
and Godfrey, 2019). For example, a 2016 report on salmon health in
Norway referred to the need for frequent, expensive sea lice treatments
as causing an increase in production costs (Hjeltnes et al., 2017), and a
study estimated that costs and losses associated with sea lice in 2011
was equivalent to 9% of Norwegian salmon farm revenues (Abolofia
et al., 2017).
The aim of this study is to better understand veterinary drug use
practices in the U.S. net pen Atlantic salmon aquaculture industry,
which fills important data gaps. We hypothesize that antimicrobial use
in U.S. salmon aquaculture is proportional to antimicrobial use in other
Western countries with salmon aquaculture industries. To test this hy-
pothesis we collected, digitized, and analyzed detailed records provided
by state agencies on Atlantic salmon production and veterinary drug
usage as well as from other salmon producing countries. We also
compared salmon drug use to terrestrial food animals in the United
States and discuss federal policy related to drug use and antimicrobial
resistance.
2. Material and methods
2.1. Overview and scope
We collected data on Atlantic salmon aquaculture production and
veterinary drug use from state and federal agencies using government
websites, online databases, and personal communications. Data col-
lection ran from November 2017 to May 2018 and covers the years
2003 to 2017. For the purposes of this study, we focused on marine net
pen Atlantic salmon production, which occurs in Maine and
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Washington, U.S. We excluded other salmonid species, such as fresh-
water trout because production methods vary considerably from
Atlantic salmon. In addition, salmon raised in land-based recirculating
aquaculture systems were excluded since it contributes little to overall
domestic salmon production.
2.1.1. Washington, U.S
During the study period, Atlantic salmon in Washington were raised
in eight production sites located in four geographic regions near the
coastline (Fig. 1). A total of 102 net pens were available for production
at all sites during the study period with a total permitted production
volume of 14,470 metric tons (Table A.1). Each site had between 8 and
20 square pens arranged in a grid. Two locations in Washington,
Deepwater Bay and Rich Passage, have the highest concentration of
production, with three production sites clustered together at each lo-
cation. Sites in Deepwater Bay are located roughly 250 and 400 m from
each other, and in Rich Passage sites are located roughly 200 and 800 m
from each other. Distance between net pen sites can be a factor in
disease management, but the relationship between the use of veterinary
drugs and density of net pen sites was outside the scope of this study.
Data on salmon production and veterinary drug use were provided
by the Washington Department of Ecology (DE) via the online portal
“Water Quality Permitting and Reporting Information System (PARIS)”
(Washington Department of Ecology, 2018). The online portal is
searchable by National Pollution Discharge Elimination System
(NPDES) permit number and provides satellite images of farms, permit
applications, correspondence between the DE and the permit applicant,
and compliance reports. The permit holder provided DE with reports on
monthly salmon biomass, monthly feed use, and monthly medicated
feed use for each permitted site, however data at the pen-level was not
reported. Monthly pdf reports from 2012 to 2017 were available and
digitized in Excel (Microsoft, Redmond, WA) by the study team for
further analysis. The database we analyzed is available in the Appendix.
The total biomass of salmon harvested in a given production cycle
was not provided in regulatory reports. To estimate total biomass, we
first determined the feed conversion ratio (FCR) for each production
cycle. We used the total feed administered during a production cycle
and the FCR to estimate the fish biomass added during grow-out in the
pens, and summed the grow-out biomass and the biomass at stocking to
obtain the total estimated biomass. Drug concentrations (grams per
feed weight) were reported for 2012 to 2014, but not 2015 to 2017;
therefore, an assumption in our analyses was that drug concentrations
for missing years were the same as for years with data, given that there
was little variation in drug concentrations from 2012 to 2014.
Antiparasitics were not administered in Washington during the range of
years with available data, and information on production or drug use
during freshwater life stage was not available. Production data were not
available from 2003 to 2010 in Washington; we instead subtracted
Maine Atlantic salmon production (Maine Department of Marine
Resources, n.d.) from U.S. Atlantic salmon production (NOAA, 2017) to
estimate Washington production, since there are only two states with
significant Atlantic salmon production. We estimated 2011 Washington
production by averaging 2010 and 2012 production.
2.1.2. Maine, U.S
In Maine, Atlantic salmon are produced at nine sites located in four
regions interspersed among small coastal islands and bays (Fig. 1). The
four regions are Cobscook Bay on the U.S.-Canadian border, Eastern
Bay, Machias Bay, and Swans Island. Three sites in Cobscook Bay are
located 1200–4100 m from each other, the four sites in Machias Bay are
Fig. 1. Map of Atlantic salmon aquaculture sites in A) Washington and B) Maine, United States during the study period.
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located 300 m from each other with one site over a kilometer away,
three sites near Swans Island are located 300 to 9700 m from each
other, and three sites in Eastern Bay are 1000 to 1700 m from each
other. A total of 193 net pens are available for production in Maine
(Table A.2). Sites had between 5 and 21 circular pens arranged in a
grid.
Maine data were provided by the Department of Marine Resources
(DMR) and the Department of Environmental Protection (DEP). DMR
maintains the Maine Aquaculture Map, an online mapping tool that
provides basic information about aquaculture leases and licenses
(Maine Department of Marine Resources, 2018). Atlantic salmon pro-
duction from 1989 to 2010, and veterinary drug use from 2001 to 2008
were available on the DEP website (Maine Department of Marine
Resources, 2009, n.d.). Data were provided by the agency via personal
request for monthly fish counts, monthly average fish weight, and
monthly veterinary drug use (antimicrobials and antiparasitics), treat-
ment concentration, duration of use (in days), reason for application,
and application method (bath, medicated feed) from 2014 to 2017.
Data were provided at the pen-level, and aggregated up to site-level
data because we observed that when veterinary drugs were adminis-
tered they were given to all pens on a site. The database we analyzed is
available in the Appendix.
Biomass was calculated by multiplying the fish count by the average
fish weight. Production data were not available from 2012 to 2017; we
instead subtracted Washington Atlantic salmon production from U.S.
Atlantic salmon production to create an estimate for Maine (FUS 2016).
We estimated 2011 Maine production by averaging 2010 and 2012
production. We averaged U.S. Atlantic salmon production from 2013 to
2015 as a proxy for production in years without data (2016 and 2017).
2.1.3. U.S. livestock and poultry
We compiled data on U.S. beef, pork, broiler chicken, and turkey
production and antimicrobial use, and compared these data to Atlantic
salmon. U.S. livestock production was accessed via the U.S. Department
of Agriculture (USDA) (USDA, 2017). Antimicrobial sales by the phar-
maceutical industry to livestock and poultry producers were reported
by the U.S. Food and Drug Administration (FDA) (FDA, 2018) as re-
quired by the Animal Drug User Fee Act. In 2016, FDA began reporting
sales of drugs by species for cattle, hogs, chickens, turkey, and an
“other” category, which includes non-food animals (e.g., pets, horses),
other minor species (e.g., quail), aquaculture, and other unknown uses.
We developed species-specific antimicrobial use rate estimates by di-
viding antimicrobial sales by production (see Table A.4 and (FDA,
2003)).
2.2. International salmon aquaculture
Atlantic salmon production and antimicrobial use data were col-
lected from multiple sources in March 2018. We reviewed farmed
salmon reports produced by the Monterey Bay Seafood Watch program
(Seafood Watch, 2018), and used these reports and online searches in
Google Scholar to identify primary source material. Norway and Chile
produce comprehensive reports on salmon production and veterinary
drug use. In Norway, open statistics for fish production in aquaculture
have been made since 1971 (Fiskeridirektoratet, n.d.), and statistics for
drug consumption in aquaculture have been available since the mid-
1980s (Bangen et al., 1994; Norwegian Institute for Public Health, n.d.;
Simonsen et al., 2016). In Chile, salmonid production and drug use data
are available in reports from 2005 to 2017 (SERNAPESCA, 2018). In
Canada, annual antimicrobial use was reported by the British Co-
lumbian salmon industry from 1995 to 2015 (BCSFA, 2016), by in-
dustry scientists from 2003 to 2011 (Morrison and Saksida, 2013), and
breakouts of specific drugs were reported by the British Columbia
Ministry of Agriculture as personal communication to Seafood Watch
(Seafood Watch, 2017a). Data from Atlantic Canada were less robust;
production data were compiled from multiple sources by Seafood
Watch (Seafood Watch, 2016) and antimicrobial use data were pro-
vided by the industry for 2012 to 2015; however, these data were
provided for the entire Atlantic North America (including Maine)
(Seafood Watch, 2016). We therefore subtracted our Maine anti-
microbial use data from Atlantic North America to estimate anti-
microbial use in Atlantic Canada. The Scottish Environmental Protec-
tion Agency provided antimicrobial use data for 2006 to 2016 as
personal communication to Seafood Watch (Seafood Watch, 2017b),
which we digitized using GraphClick (v. 3.0.3, Arizona). Scottish
salmon production was calculated by the Scottish government (Munro
and Wallace, 2017). For countries where multiple salmonids are pro-
duced in marine waters, we combined them.
2.3. Software
Data were stored and analyzed in Excel and graphed in Prism (v.7,
GraphPad, La Jolla, CA). Maps of salmon aquaculture facilities were
made using ArcGIS (ESRI, Redlands, CA).
3. Results
3.1. Washington Atlantic salmon production and antimicrobial use
Fig. 2 presents Atlantic salmon biomass and antimicrobial use on a
monthly basis over a six-year period at eight production sites (a total of
21 production cycles). The grow-out periods were slightly less than two
years, and pens were restocked after two to four months of fallowing.
Actual production volumes were similar to NPDES permitted produc-
tion volumes (Table A.1). The average feed conversion ratio was
1.5 ± 0.4 for the nearly thirty grow-out periods. There was no cor-
relation between FCR and drug use in a production cycle. (Fig. A.5
presents additional production and antimicrobial use data from January
2018 to Septeember 2019.)
Antimicrobial drugs (florfenicol, sulfadimethoxine and ormetoprim
in a 5:1 mixture, and oxytetracycline) were administered as medicated
feed for disease treatment (Table 1). Antimicrobials were used in 93%
(26 of 28) of production cycles (Fig. 2). Disease events are visible as
clusters of months with antimicrobial use (Fig. 2). Florfenicol or sul-
fadimethoxine/ormetoprim was regularly administered after fish were
stocked into pens, including some months when both florfenicol and
sulfadimethoxine/ormetoprim were used. Sulfadimethoxine/ormeto-
prim was used more often in summer months and oxytetracycline in
summer and fall, while florfenicol did not appear to have seasonal
usage patterns (Fig. A.1).
Florfenicol, sulfadimethoxine/ormetoprim, and oxytetracycline
were reported in NPDES permitting documents to be administered at
doses of 10, 50 and 75 mg/kg fish, respectively for a 10-day duration
(florfenicol and oxytetracycline) or a 5-day duration (sulfadi-
methoxine/ormetoprim) (Table 1).
3.2. Maine Atlantic salmon production, antimicrobial use, and antiparasitic
use
Fig. 3 presents Atlantic salmon biomass and veterinary drug use on a
monthly basis over a 4-year period from 2014 to 2017 at thirteen sites
(a total of 17 production cycles). The grow-out periods were 20 to
28 months, and pens were restocked after a period of fallowing of five
to 12 months. Oxytetracycline is the only antimicrobial used in Maine,
which is administered as a medicated feed to treat bacterial kidney
disease (BKD) (Table 1). Before an antimicrobial is used, Maine farmers
identify the pathogen, perform sensitivity testing, and post a public
notice that antimicrobials are in use (Sebastian Belle, Personal Com-
munication). From 2014 to 2017 oxytetracycline was used in 24% (5/
21) of production cycles, and additional data was provided for earlier
years by Sebastian Belle (Personal Communication) indicating that 8%
(13/166) of production cycles from 2003 to 2017 used oxytetracycline.
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There was a seasonal pattern in drug use from 2014 to 2017, with
higher use during summer months (Fig. 2A). The reported duration of
treatment was 8 days (st dev: 4 days; range: 2–15 days) and the dosage
rate was 70 ± 15 mg/kg fish/day (Table 1).
Sea lice was treated with a medicated feed containing emamectin
benzoate (SLICE®) and then a subsequent treatment with a hydrogen
peroxide bath, but not as a combined treatment (Table 1). Similar to
antimicrobials, pathogen identification and sensitivity testing are per-
formed before antiparasitics are administered (Sebastian Belle, Personal
Communication). Fish at Cobscook Bay and Machias Bay received more
sea lice treatments than other sites. Emamectin benzoate was used in
62% of production cycles (13/21) from 2014 to 2017 with a total use of
4.5 kg (active ingredient). Additional data was provided for earlier
years by Sebastian Belle (Personal Communication) showing that 28%
(46/166) of production cycles from 2003 to 2017 used emamectin
benzoate. The dosage was similar to the INAD approved dose of
0.05 mg/kg fish/day (US Fish and Wildlife Service, n.d.) and the
average duration of use was 6 days (st dev: 3 days; range: 1–11 days)
(Table 1). Hydrogen peroxide was administered in months following
treatment with emamectin benzoate, at a concentration of 1200 to
1750 mg/l. No seasonal trends emerged regarding use of emamectin
benzoate and hydrogen peroxide (Fig. A.2).
Fig. 2. Washington, United States Atlantic salmon monthly biomass (metric tons, black lines left y-axis) and monthly antimicrobial use (kg, colored circles, right y-
axis) at eight sites from January 2012 (month 0) to December 2017 (month 72). (For interpretation of the references to colour in this figure legend, the reader is
referred to the web version of this article.)
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3.3. Global salmon production and antimicrobial use
A total of 382,500 kg of antimicrobials were used globally in 2016
(Table 2), which is the most recent year with data from all producing
regions. Florfenicol was the most often used drug (318,558 kg in 2016)
and 80% of florfenicol use was in Chile. (Figs. A.3 and A.4 and Tables
A.5 – A.7 provide production statistics, antimicrobial use, and anti-
microbial use rates by region from 2003 to 2017). Over the most recent
three-year period with complete data (2014 to 2016), the U.S. farmed
salmon industry contributed 0.8% ± 0.1% annually to global farmed
salmon production and administered 1.2% ± 0.6% of antimicrobials
used in global salmon farming. Over the same time period, Norway and
Chile accounted for 53% ± 3% and 35% ± 3% of global production
and administered 0.06% ± 0.02% and 96% ± 0.09% of global
salmon antimicrobials.
Fig. 4 presents antimicrobial use rates [e.g., total drugs used (mg)
divided by total salmon produced (kg)] for major salmon producing
countries. Norway, Scotland, British Columbia, and Maine have made
significant progress towards reducing antimicrobial use, and Maine
producers did not use antimicrobials from 2006 to 2011 or in 2017.
Washington had the highest rate of antimicrobial use for 2012, 2013,
and 2016. There were not enough available data on salmon production
in Atlantic Canada to determine trends; however, total antimicrobial
usage has dropped from 2013 to 2016 (Fig. A.3).
Table A.3 compares antimicrobial drug use rates by country from
2003 to 2017. We observed that reductions in use of certain anti-
microbials and increases in others have occurred simultaneously. For
example, in British Columbia there was a decrease in oxytetracycline
and sulfadiazine/trimethoprim use over the past decade, and a con-
current increase in florfenicol. The Chilean industry reduced usage of
oxolinic acid and flumequine and also had concurrent increases in
florfenicol. Reductions in Scotland were largely through decreased use
of oxytetracyline.
3.4. Comparing U.S. livestock and Atlantic salmon production and
antimicrobial use
A total of 13,639 metric tons of antimicrobials were used by U.S.
food animals in 2016 (Table 3). Cattle, hog, poultry, and turkey used
49%, 26%, 16%, and 8% of antimicrobials available for food animals.
U.S. Atlantic salmon used 0.057% of all food animal drugs and account
for 0.031% of U.S. food animal production by weight.
Roughly 8000 metric tons of medically important drugs were sold
for use in U.S. food animals in 2016. (The term “medically important” is
defined by the U.S. Food and Drug Administration as drug classes that
have importance in human medicine (FDA, 2003)). Cattle, hog, turkey,
and poultry used 45%, 39%, 9%, and 6% of medically important drugs
available for food animals. U.S. Atlantic salmon used 0.098% of these
medically important drugs. Tetracyclines were the most used class of
medically important drugs in all animals (Table A.4).
4. Discussion
4.1. Antimicrobial use and resistance
Antimicrobial resistance is a worldwide public health crisis where
the overuse or misuse of antimicrobials in any setting—aquaculture,
agriculture, or human medicine—can compromise the treatment of
bacterial infections in animals and humans (Ferri et al., 2017). The
significance of this crisis for human health cannot be overstated. Un-
successful antimicrobial therapy in 2016 caused an estimated 700,000
global fatalities and could cause 10 million fatalities by 2050 (Review
on Antimicrobial Resistance, 2016). Many of the antimicrobials used in
aquaculture are from drug classes considered “critically important” or
“highly important” for human medicine (FDA, 2003; WHO, 2017b) and
have been found to select for antimicrobial resistant bacteria when used
in aquaculture production (Cabello, 2006; Cabello et al., 2013; Sapkota
et al., 2008; Watts et al., 2017). The degree to which salmon aqua-
culture contributes to global antimicrobial use is well established for
the major salmon producing countries (Cabello et al., 2013; Miranda
et al., 2018; SERNAPESCA, 2018; Smith et al., 2010). It is widely known
that Norway, the largest salmon producing nation has almost com-
pletely stopped antimicrobial use, while Chile, the second largest
salmon producing nation accounts for most of global salmon anti-
microbials use. Antimicrobial use in U.S. salmon aquaculture, however,
has not been compiled or reported previously until this study. Drug
usage was higher in Washington than Maine, and antimicrobial use
rates (total drugs used divided by total salmon produced) in Wa-
shington were higher than several other salmon producing regions.
Surveillance, monitoring, and reporting of antimicrobial use in food
animal production is an important component of national antimicrobial
resistance policies, as antimicrobial use is proportional to antimicrobial
resistance (WHO, 2017a). Large data gaps exist for many aquaculture
species (Henriksson et al., 2017). Farmed salmon producers report
antimicrobial use, and from these reports we estimate that anti-
microbial use in global salmon aquaculture is 398 tons (in 2016) and
can be compared to the 13,631 tons of antimicrobials sold to the U.S.
livestock and poultry industries (FDA, 2018) and to the estimated
Table 1











Florfenicol Feed 10 10 0.66 15 Bacterial pathogens
Sulfadimethoxine -
ormetoprim
Feed 50 5 5 n/a Furunculosis, vibrio, myxobacterial
and other bacterial pathogens
Oxytetracycline Feed 75 10 11 n/a Furunculosis, vibrio, myxobacterial
and other bacterial pathogens
Maine
Oxytetracycline Feed 70 ± 15 8 ± 4 2.8–11.9 n/a Bacterial kidney disease
Emamectin benzoate Feed 0.044 ± 0.01 6 ± 3 0.0016–0.0056 60 Sea lice
50% hydrogen peroxide Bath 1200–1750c 1 1200 - 1750 0 Sea lice
35% hydrogen peroxide Bath 1750c 1 1750 0 Sea lice
a Common names for drugs: Aquaflor = florfenicol; Romet 30 = sulfadimethoxine-ormetoprim; Terramycin 200 = oxytetracycline; SLICE = Emamectin
benzoate; Interox Paramove 50 = 50% hydrogen peroxide; Perox-Aid = 35% Hydrogen Peroxide.
b In Washington, proposed dosage is provided in the NPDES permit. In Maine, dosage was calculated based on reported drugs use and duration, number of fish per
pen, and average fish weight. The calculated dosage in Maine was similar to the approved dosage.
c Reported in units (mg/l).
d Conversion to g/lb.: Aquaflor (0.3 g/lb); Romet-30 (2.27 g/lb); Terramycin 200 (5 g/lb. WA, 1.3–5.4 g/lb. ME).
D.C. Love, et al. Aquaculture 518 (2020) 734820
6
63,000 tons of antimicrobials administered to terrestrial livestock
globally (Van Boeckel et al., 2015). There are notable distinctions be-
tween antimicrobials used in aquaculture and terrestrial species and
comparisons of antimicrobial use between livestock and fish need to be
made with caution (Henriksson et al., 2015). Fish receive anti-
microbials for therapy and not growth promotion (which were pre-
viously allowed for U.S. livestock), and drugs administered orally to
fish via medicated feed raise different sets of issues than drugs ad-
ministered orally to terrestrial animals due to the aquatic setting and
biological differences.
One factor causing potentially increased consumption rates of an-
timicrobials in marine fish is that some drugs are known to have low
bioavailability in seawater systems. Tetracyclines are prone to bind
calcium and magnesium from seawater, and their absorption in fish is
reduced (Lunestad and Goksøyr, 1990). These drugs enter the aquatic
environment associated to organic material such as un-eaten medicated
pellets and feces, and as a water-soluble fraction if eliminated via gills,
feces and urine. It has been estimated that approximately 80% of the
antimicrobials used in aquaculture enter the environment with their
activity mostly intact (Cabello et al., 2013). While the water-soluble
fraction is diluted in the surrounding water, much of the drug asso-
ciated to organic material will settle on the seabed, bound to solid
matter (feed, excreta, etc). The amount of drug reaching the sediment
depends on the fraction of un-eaten pellets and the pharmacokinetic
Fig. 3. Maine, United States Atlantic salmon monthly biomass (metric tons, black lines, left y-axis) and monthly veterinary drug use (kg, colored circles, right y-axis)
at 13 sites from April 2014 (month 4) to December 2017 (month 48). (For interpretation of the references to colour in this figure legend, the reader is referred to the
web version of this article.)
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properties (absorption rate, metabolism and elimination pathway) of
the drug in the fish. If the absorption and metabolism is low, most of the
consumed drug will be eliminated as the parent compound via the liver
and bile to the intestine and if readily associated with particles rich in
organic content, the fecal particles may contain concentrations of the
drug higher than the original pellets. Once reaching the sediment,
factors like water solubility, affinity for organic particles, photo-stabi-
lity and microbial and chemical degradation determine the persistence
of the drug in the sediment (Lunestad et al., 1995; Samuelsen et al.,
1994). Drugs are associated with small, slow sinking organic particles
that may be transported a long distance before settlement (Buschmann
et al., 2012; Capone et al., 1996). For example, in Norway, following
medication with anti-sea lice agents at near shore cage operations, or-
ganic material collected one km away from the fish farm using sediment
traps contained detectable drug residues (Samuelsen et al., 2015). Re-
sidues of oxolinic acid were found in wild fish, crustaceans, and bi-
valves near two marine salmon farms in western Norway that used this
medication in feed (Samuelsen et al., 1992).
In addition, the use of antimicrobials in salmon farms could create
hotspots for potential selection and generation of novel antimicrobial
resistant bacteria and new assortments of antimicrobial resistance genes
in the environment and in farmed fish (Cabello et al., 2016; Higuera-
Llantén et al., 2018). Antimicrobial resistance genes could be taken up
by mobile genetic structures including plasmids and integrative con-
jugative elements (ICEs), which can pass from one bacteria to another
by horizontal gene transfer (Cabello et al., 2013). Antimicrobial re-
sidues, even at sub-inhibitory concentrations, can also stimulate mu-
tagenesis, genetic recombination in integrons and horizontal gene
transfer, increasing genetic variation fostering new antimicrobial re-
sistance combinations (Friman et al., 2015; ter Kuile et al., 2016; You
and Silbergeld, 2014). Moreover, use of antimicrobials in salmon
aquaculture may facilitate the selection and capture by piscine and
human pathogens of new antimicrobial resistance genes present in the
yet unexplored marine resistome (Cabello et al., 2017; Fonseca et al.,
2018). These concerns are not unique to salmon aquaculture, and exist
for any food animal production system in which antimicrobials are
used.
Antimicrobial drugs released from farms have been shown to select
for antimicrobial resistance in environmental bacteria (Bravo, 2012),
fish pathogens (Sørum, 2006), marine sediment (Buschmann et al.,
2008; Shah et al., 2014), and possible human pathogenic bacteria (Aedo
et al., 2014; Buschmann et al., 2012; Heuer et al., 2009). A study in
Washington found drug residues and antimicrobial resistance in sedi-
ments near salmon aquaculture sites (Capone et al., 1996; Herwig et al.,
1997). Human diseases caused by multi-resistant bacteria are infre-
quently linked to the consumption of seafood. An epidemiologic in-
vestigation in Ecuador found eating raw fish (not reported as farmed or
wild caught) was associated with illnesses caused by multidrug resistant
Vibrio cholerae (odds ratio: 10.0, confidence interval: 1.2–85.6) (Weber
et al., 1994). Multidrug resistant and potentially pathogenic bacteria
have been isolated in seafood from Brazil (Teophilo et al., 2002), India
(Das et al., 2019), Nigeria (Igbinosa et al., 2019), the Philippines
(Tendencia and de la Peña, 2001) and Thailand (Petersen and
Dalsgaard, 2003). Researchers have detected several genetic elements
conferring antimicrobial resistance to quinolones, tetracyclines, and β-
Table 2
Salmon antimicrobial use (kg) by drug type and country, 2016.
Drug Class, drug United States Canada Scotland Norway Chile
ME WA Atl CAa BC
Macrolide
Erythromycin – – n/a – – – 11,475
Amphenicol
Florfenicol – 57 n/a 2727 76 136 315,563
Quinolones
Flumequine – – – – – – 11,475
Oxolinic acid – – – – – 66 –
Tetracycline
Oxytetracycline 1946 5634 n/a 2396 – – 64,260
Potentiated sulfonamides
Sulfadiazine/trimethoprim – – n/a – – – –
Sulfadimethoxine/ormetoprim – 194 – 95 – – –
Total 1946 5885 2343 5218 76 201 382,500
a Total antimicrobial use was available for Atlantic Canada, but not available by drug type. n/a = not available but reported in previous years (2012–2014).
Fig. 4. Salmon aquaculture antimicrobial rates (mg/kg fish) by country or US
state (2003–2017). Antimicrobial use rates (mg/kg) were calculated by dividing
annual antimicrobial use by annual production (data provided in Tables A.5 –
A.7). Data for Norway is based on all farmed fish species and Chile is based all
salmonids (including Atlantic salmon, coho salmon, and rainbow trout). Salmon
constitutes approximately 95% of the producting in Norway and Chile.
Table 3
United States animal production and antimicrobial use (metric tons), 2016.
Speciesa Live weight Antimicrobial use Percent of
antimicrobial use
Beef 18,222,708 6727 49%
Pork 15,600,494 3559 26%
Chicken 25,999,221 2209 16%
Turkey 3,434,154 1136 8%




Atantic salmon, Maine 12,798 1.95 0.014%
Total 63,276,291 13,639 100%
a Salmon is compared to the top four U.S. food animal products. Livestock
values based on sales of antimicrobial drugs and not actual usage. Antimicrobial
drug use was not available for other species.
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lactames that are shared between aquatic bacteria, fish pathogens, and
human pathogens, and they appear to have originated in the aquatic
environment (Cabello et al., 2013). Research has not adequately as-
sessed whether antimicrobial use and resistance at salmon aquaculture
farms could affect workers and residents living near farms, as previous
research has shown for terrestrial animals (Casey et al., 2015; Hatcher
et al., 2016).
4.2. Fish health and disease management
Diseases cost the global aquaculture industry $6 billion (U.S.) dol-
lars each year (World Bank, 2014). The largest recent disease outbreak
of ISA in salmon occurred in 2007 in Chile and cost the industry $2
billion and 20,000 jobs (World Bank, 2014). Even with enhanced bio-
security and optimized husbandry, the aquatic environment remains
fertile ground for disease outbreaks associated with traditional or
emerging pathogens, especially when hosts are exposed to inevitable
stressors that occur throughout the fish production cycle.
Best management practices (BMPs) to prevent and control diseases
in salmon net pen aquaculture have been summarized previously (Belle
and Nash, 2009). BMPs include i) judicious site selection to ensure
adequate water exchange; relative safety from extreme weather events,
algal blooms, and/or concentrations of predators; and adequate water
depth and sea bottom profile; ii) the use of high quality diets and ef-
fective methods for both feed dissemination and monitoring feed con-
sumption; iii) rotation of rearing sites within a production area, in-
cluding leaving individual sites empty (fallow) for specified periods;
and iv) biosecurity BMPs including the adoption of an all-in, all-out
population management plan (i.e., not mixing cohorts) and the avoid-
ance of shared use of equipment (e.g., well boats) between production
sites. Many of these BMPs go beyond what government regulators re-
quire, and instead are driven by corporate and industry-wide efforts.
For example, an industry group, the Global Salmon Initiative (GSI), has
a goal of having 100% of salmon farms operated by GSI members
certified by the Aquaculture Stewardship Council by 2020 (Global
Salmon Initiative, 2018). This is an example of market-driven aqua-
culture certification setting international standards, which can aid in
enforcement and compliance using third party auditors (Henriksson
et al., 2017; Jonell et al., 2013).
In addition to BMPs, general lessons from Norway regarding anti-
microbial use could be applied to other countries. Norway has extensive
experience in disease management as a means of controlling anti-
microbial use. Substantial decreases have been seen in the use of an-
timicrobials in aquaculture since 1987 (Grave et al., 1999; Simonsen
et al., 2013). The main reason for this is the application of effective
vaccines added oil adjuvants against the main bacterial infective
agents, along with additional factors such as zoning and farm siting to
prevent horizontal transmission of infectious disease, using ‘all-in-all-
out’ production systems, and mandating fallowing periods between
year classes (Midtlyng et al., 2011; Sommerset et al., 2005). Norway
and other producing countries continue to struggle with control of sea
lice (Hjeltnes et al., 2017).
Another way of reducing disease pressure in aquaculture is by
raising fish in relatively disease-free environments and using disease
free brood lines. As growth in coastal production locations becomes
constrained, there is increasing interest to implement land-based,
closed containment production of Atlantic salmon, with the added
benefit to potentially remove disease transfer between wild and farmed
salmon (Summerfelt and Christianson, 2014). Through the use of spe-
cific pathogen-free eggs, biosecure groundwater, and effective biose-
curity protocols and personnel management, the risk of obligate pa-
thogen introduction can be minimized (Timmons and Ebeling, 2007).
Disease associated with ubiquitous opportunistic pathogens, however,
must always be considered regardless of rearing system type. Proper
care must be taken to reduce stress due to the intensive, high-density
environment, particularly since water is often recirculated, potentially
allowing pathoges to proliferate to dangerous levels. Furthermore, in-
tensive land-based production provides a novel environment for
Atlantic salmon, and it is probable that novel diseases and/or pathol-
ogies will emerge as this industry sector continues to expand.
4.3. Antibiotics in U.S. aquaculture
There are a series of ongoing efforts by the U.S. FDA aimed at re-
forming antimicrobial use in U.S. food animal production. Recent FDA
policies have: i) phased-out drugs for production purposes (i.e, growth
promotion), however aquaculture does not use drugs for this purpose;
ii) phased-out over-the-counter (OTC) drug sales; iii) decreased the use
of medically important antimicrobials by 43% from 2015 to 2017; and
iv) created veterinarian-client-patient relationships in which a veter-
inarian must issue a written statement (called a Veterinary Feed
Directive (VFD)) in order to use VFD drugs (FDA, 2012, 2013, 2015,
2018). Several agencies in the federal government are monitoring drug
sales and antimicrobial resistance in humans and meat to understand
the significance of the issue for public health. These initiatives could
impact the aquaculture industry in the following ways.
The first is the federal VFD rule that affects how aquaculture drugs
are prescribed. Drugs previously sold OTC for extra-label uses (in-
cluding oxytetracycline and sulfadimethoxine/ormetoprim used in
salmon) became VFD drugs starting in January 1, 2017 (FDA, 2016).
Our dataset ends December 2017, one year after the VFD went into
effect, and it appears that high use of oxytetracycline in Washington
may be related to the drug's OTC status. (Washington data from Jan-
uary 2018 to September 2019 is presented in Fig A.5 but not analyzed
as part of this study). Sulfadimethoxine/ormetoprim was sold OTC in
Washington as well; however, there are fish toxicity concerns with this
drug which explains why the dose and duration of use rarely exceeded
the extra-label use requirements. Florfenicol was under a VFD
throughout this study and usage appeared to be consistent wtih the
INAD label requirements. Future studies could assess what impact the
VFD rule has on antimicrobial use in the aquaculture industry more
broadly.
Reporting requirements are a second area where government policy
could impact aquaculture. State regulators already collect data on
salmon production to comply with NPDES permits, and Maine reg-
ulators also require salmon producers to provide a written request to
use and discharge any new drugs, and post public notice that farms are
using therapeutants. Regulators base their decision to approve or reject
the request on whether the drug will have “significant adverse impacts
on receiving water quality” (Personal communication, Maine
Department of Environmental Protection). If net pen operations shift
from state to offshore water would a federal agency provide a similar
role in drug use reporting? Federal regulators who oversee offshore
aquaculture could consider using Washington and Maine as models for
reporting and public disclosure of monthly veterinary drug use at each
farm site. Current federal antimicrobial reporting is done through the
Animal Drug User Fee Act (ADUFA) in which the FDA reports sales of
antimicrobials made by the pharmaceutical industry for use in select
species (for cattle, pigs, chickens, and turkeys) (FDA, 2018). Annual
ADUFA sales data are less relevant for public health measurements than
monthly, farm-level drug use data. Additonally, ADUFA combines
aquaculture with other groups of animals (including pets and horses),
and future reports should consider break-out analyses for aquaculture,
which would allow for better comparison to other food animal in-
dustries.
A third area is monitoring of drug residues and antimicrobial re-
sistance at farms and in the food system. Maine and Washington reg-
ulators have the ability to request that the industry monitor the farm
environment for drug residues or antimicrobial resistant bacteria, re-
spectively, but have not done so recently (Maine DEP, Personal
Communication). Regular monitoring is required, for example, in
Maine for sulfides, which can trigger additional regular testing of
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benthic infauna. Our study findings suggest that routine monitoring of
drug residues and antimicrobial resistant bacteria may be useful in
Washington. It is in the best interest of the salmon industry, and for the
health of the aquatic ecosystem, that its activities do not alter biodi-
versity and do not select for antimicrobial resistant bacteria, including
piscine and human pathogens. Beyond the farm, several U.S. agencies
work together to monitor antimicrobial resistance in humans and retail
meats in a program called the National Antimicrobial Resistance
Monitoring System (NARMS, 2015). This program samples retail live-
stock and poultry meat but excludes domestic aquaculture products,
which should be added in the future.
There are several limitations to this study. There were some data
gaps that required estimation, such as salmon production data for some
years in Washington, Maine, and national data, also drug concentra-
tions in Washington were estimated for some years based on other years
with reported data. We reported Maine and Washington veterinary drug
use on a monthly and annual basis, however, Maine data were provided
on a more granular basis for some years. Data on veterinary drug use in
freshwater life stages of salmon were not available for most countries
including the U.S. The reason for drug administration (i.e., name of fish
disease) was not provided with monthly data in Washington.
Antimicrobial use in U.S. salmon was compared to antimicrobials sales
data for U.S. livestock, which is not an ideal comparison because sales
do not necessarily equate to use.
5. Conclusions
The U.S. net pen Atlantic salmon aquaculture industry is the first
U.S. food animal industry we are aware that reports to the government
with monthly antimicrobial use at the farm-level. Many of the anti-
microbials used in aquaculture, including those in U.S. aquaculture, are
from drug classes that are “critically important” or “highly important”
for human medicine. Based on our data, the U.S. net pen Atlantic
salmon industry is a minor contributor to antimicrobial drug use
comparted to U.S. beef, pork, and poultry and Chilean salmon in-
dustries. There are relatively few approved drugs in the U.S. available
to treat aquaculture diseases and more options are needed as well as
continued work on vaccines. We anticipate that the VFD rule will fur-
ther reduce antimicrobial usage by removing over-the-counter drug
sales. Antimicrobials and antiparasitics used to treat farmed salmon
diseases can select for resistance in target organisms. Tracking anti-
microbial use in all types of food animal production is an important
component of national and international antimicrobial resistance pre-
vention policies.
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